IDH1 Antibody

What is IDH1 and why is it significant in cancer research?

IDH1 is an enzyme that catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, producing NADPH. It is the NADP+-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes . IDH1 mutations, particularly the R132H mutation, have been reported in multiple cancers including glioblastoma, acute myeloid leukemia (AML), and other malignancies . IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway .

What types of IDH1 antibodies are available for research?

Researchers can utilize several types of IDH1 antibodies:

• Wild-type IDH1 antibodies that detect the normal protein

• Mutation-specific antibodies (particularly IDH1 R132H)

• Various formats including:

  • Rabbit monoclonal antibodies

  • Mouse monoclonal antibodies

  • Rabbit polyclonal antibodies

Each antibody type has specific applications and sensitivity profiles. For example, MRQ-67 (a rabbit monoclonal antibody) has demonstrated higher binding capacity compared to mouse monoclonals in comparative studies .

What is the difference between wild-type IDH1 antibodies and IDH1 R132H-specific antibodies?

Wild-type IDH1 antibodies detect the normal IDH1 protein regardless of mutation status, making them useful for total IDH1 expression studies. In contrast, IDH1 R132H-specific antibodies selectively bind only to the mutant protein containing the R132H substitution, enabling specific detection of this mutation . The mutation-specific antibodies are critical for diagnostic applications, as they can distinguish between wild-type and mutant protein in tissue samples, particularly in gliomas where IDH1 R132H mutation has significant diagnostic and prognostic implications .

What are the optimal methods for detecting IDH1 mutations in clinical samples?

Multiple methods can be used for IDH1 mutation detection, each with distinct advantages:

Based on research findings, a combined approach is often optimal: IHC with IDH1 R132H-specific antibodies for initial screening, followed by sequencing of negative cases to detect non-R132H mutations .

How should IDH1 R132H immunohistochemistry protocols be optimized?

For optimal IDH1 R132H IHC protocol:

• Fixation: Use formalin-fixed, paraffin-embedded (FFPE) tissue sections

• Epitope retrieval: Perform heat-induced epitope retrieval (HIER) at pH 9 with a pressure cooker for 1.5-3 minutes

• Blocking: For HRP detection systems, block with peroxidase blocking solution for 10-15 minutes at room temperature

• Primary antibody dilution:

  • For automated systems (Ventana BenchMark ULTRA): 1:50-1:100

  • For manual staining: 1:50-1:200

• Detection system: UltraView DAB IHC or equivalent

• Automated protocol parameters:

  • Pretreatment: CC1 32-64 minutes at 100°C

  • Primary antibody incubation: 32 minutes at 36°C

Significantly, studies show that some antibody clones like MRQ-67 demonstrate less background staining compared to others like H09, which may require additional optimization to reduce non-specific staining .

How can I quantitatively assess IDH1 mutation expression levels?

Quantitative assessment of IDH1 mutation can be performed using:

• Real-time PCR (qPCR): Using specific primers for IDH1 mutation and wild-type IDH1, researchers established a reliable cutoff value above which sensitivity and specificity for detecting IDH1 mutations were 98% and 94%, respectively, compared to DNA sequencing . This method allows precise quantification of IDH1 mutation expression levels across different samples.

• Western Blot analysis: For protein-level quantification, Western blot using IDH1 R132H-specific antibodies can provide semi-quantitative data on mutant protein expression. Signal intensity should be normalized to β-actin or other housekeeping proteins .

• Dot immunoassay: This method can assess binding capacity of different antibodies to synthetic peptides representing wild-type and mutant IDH1, providing a semi-quantitative assessment of mutation levels .

Research data indicates that IDH1 mutation expression is upregulated in secondary glioblastoma (mean ± standard error of mean: 3.52 ± 0.55) compared to lower grade gliomas (WHO grade II = 1.54 ± 0.22; WHO grade III = 1.67 ± 0.23) .

How can IDH1 antibodies be used to distinguish between primary and secondary glioblastomas?

IDH1 R132H antibodies serve as powerful tools for distinguishing between these glioblastoma subtypes:

• Immunohistochemical testing: Studies show that IDH1 R132H antibodies like MRQ-67 demonstrate positive signal in most diffuse astrocytomas (16/22), oligodendrogliomas (9/15), and secondary glioblastomas (3/3), but not in primary glioblastomas (0/24) . This differential staining pattern allows for histological distinction between primary and secondary glioblastomas.

• Quantitative expression analysis: Secondary glioblastomas show significantly higher IDH1 mutation expression (mean ± SEM: 3.52 ± 0.55) compared to lower-grade gliomas , providing another method to distinguish tumor types.

• Combined molecular analysis: Integrating IDH1 mutation status with other molecular markers (such as 1p/19q co-deletion for oligodendrogliomas) enables comprehensive classification according to the WHO 2016/2021 integrated diagnostic approach.

This distinction has important prognostic implications, as secondary (IDH1-mutant) glioblastomas generally have better prognosis compared to primary glioblastomas .

What are the critical controls needed for reliable IDH1 immunohistochemistry?

For rigorous IDH1 R132H immunohistochemistry, the following controls are essential:

• Positive tissue control:

  • Use known IDH1 R132H-positive tissue samples (diffuse astrocytoma or oligodendroglioma)

  • Process and embed identically to test samples

  • Should demonstrate appropriate staining pattern (diffuse cytoplasmic reactivity)

• Negative tissue control:

  • Use known IDH1 R132H-negative tissue samples

  • Primary glioblastomas typically serve as excellent negative controls

  • Should show absence of specific staining

• Nonspecific negative reagent control:

  • Replace primary antibody with nonspecific immunoglobulin

  • Use on adjacent sections of test samples

  • Helps evaluate nonspecific background staining

• Cell line controls:

  • HEK-293T cells overexpressing IDH1 R132H (positive control)

  • HeLa IDH1 knockout cell line (negative control)

DNA sequencing verification of a subset of samples can further validate IHC results. Studies show 100% concordance between IDH1 R132H IHC positivity and sequencing confirmation of the R132H mutation .

How can I troubleshoot background staining issues with IDH1 R132H antibodies?

Background staining is a common challenge with IDH1 R132H antibodies. Research comparisons between different antibody clones reveal several approaches to minimize this issue:

• Antibody selection:

  • MRQ-67 (rabbit monoclonal) exhibited less background (8% of samples) compared to H09 (mouse monoclonal, 48% of samples)

  • Consider testing multiple antibody clones if background is problematic

• Titration optimization:

  • Reducing H09 concentration from 3.25 μg/mL to 1.63 μg/mL removed background in most samples, though signal intensity was also reduced in 40% of diffuse gliomas

  • Optimal concentration may lie between 1.63-3.25 μg/mL for H09

  • For MRQ-67, standard concentrations show minimal background

• Tissue-specific considerations:

  • Meningioma specimens are particularly prone to nonspecific staining in fibrous tissue components

  • Special attention to result interpretation is needed with certain tissue types

• Protocol modifications:

  • Extended blocking steps

  • Additional washing steps

  • Use of specialized blocking reagents for problematic tissues

These approaches should be systematically tested when troubleshooting background staining issues.

What is the utility of IDH1 antibodies in studying other cancer types?

While most prominently used in brain tumor research, IDH1 antibodies have important applications in other cancer types:

• Acute myeloid leukemia (AML):

  • Studies demonstrate prevalence of IDH1 and IDH2 mutations at 8.7% (20/230) and 10.4% (24/230), respectively

  • IDH1 antibodies can be used for research into AML pathogenesis and for stratifying patients in experimental studies

• Acute lymphoblastic leukemia (ALL):

  • Research found IDH1 mutations (R132H, R132G, R132S) in 3 of 54 adult ALL cases

  • No IDH1 or IDH2 mutations were detected in pediatric ALL (0/34 cases)

  • Antibodies can help identify rare IDH1-mutant cases for further molecular characterization

• Colorectal cancer research:

  • IDH1 antibodies have been used to study exosomal IDH1 and its role in resistance to 5-Fluorouracil

  • Can detect IDH1 expression in cell models of colorectal cancer

• Non-small cell lung cancer:

  • Used to investigate metabolic diversity in human non-small cell lung cancer cells

  • Can help elucidate IDH1's role in cancer metabolism

These applications demonstrate the versatility of IDH1 antibodies beyond their classical use in neuro-oncology.

How can IDH1 antibodies be integrated with other molecular techniques for comprehensive tumor profiling?

Comprehensive tumor profiling requires integration of multiple molecular techniques with IDH1 antibody-based detection:

• Combined immunohistochemistry approaches:

  • Multiplex IHC with IDH1 R132H alongside other markers (ATRX, p53)

  • Helps classify diffuse gliomas according to 2016/2021 WHO classification

• Integration with sequencing techniques:

  • IHC screening followed by targeted sequencing of negative cases

  • Next-generation sequencing panels incorporating IDH1/2 alongside other cancer-related genes

  • Whole exome sequencing for comprehensive mutational profiling

• Single-cell technologies:

  • Combined single-cell RNA and T cell receptor sequencing has been used alongside IDH1 mutation analysis in vaccine studies

  • Revealed that tumor-infiltrating CD40LG+ and CXCL13+ T helper cell clusters in a patient with pseudoprogression were dominated by a single IDH1(R132H)-reactive T cell receptor

• IDH1 in therapeutic development:

  • Antibodies used to validate IDH1(R132H)-specific peptide vaccines

  • Vaccine-induced immune responses observed in 93.3% of patients across multiple MHC alleles

  • Studies showed high three-year progression-free (0.63) and death-free rates (0.84) in vaccine trials

This integrated approach provides more comprehensive tumor characterization than any single method alone.

How do different IDH1 antibody clones compare in sensitivity and specificity?

Various IDH1 antibody clones show significant differences in performance characteristics:

Research directly comparing MRQ-67 and H09 showed that both demonstrated positive signal with similar patterns and equivalent intensities in IDH1 R132H-positive samples, but H09 exhibited background stain more frequently . DNA sequencing on 18 samples confirmed the R132H mutation in all IHC positive cases (5/5) and its absence in negative cases (0/13) for both antibodies .

What are the advantages and limitations of using IDH1 antibodies compared to molecular techniques?

Both antibody-based and molecular approaches have distinct advantages and limitations:

Research indicates that qPCR with specific primers for IDH1 mutation has high concordance with sequencing results (sensitivity 98%, specificity 94%) , offering a quantitative alternative to IHC when cellular localization is not required.

How can I validate a new IDH1 antibody for research applications?

A comprehensive validation protocol for new IDH1 antibodies should include:

• Binding specificity assessment:

  • Enzyme-linked immunosorbent assay (ELISA) comparing binding to wild-type vs. mutant peptides

  • Western blot analysis using:

    • Cell lines with known IDH1 status (e.g., HepG2 for wild-type)

    • IDH1 knockout cell lines as negative controls

    • Cells engineered to express IDH1 R132H

• Immunoassay characterization:

  • Dot immunoassay with synthetic peptides at concentrations ranging from 1 μg/mL to 1.6×10⁻³ μg/mL

  • Western blot with cell lysates (50 μg protein/well recommended)

• IHC validation:

  • Panel of known positive cases (diffuse astrocytomas, oligodendrogliomas)

  • Panel of known negative cases (primary glioblastomas)

  • Comparison to established antibody clones

  • Background assessment across multiple tissue types

• Molecular verification:

  • DNA sequencing of a subset of tested samples

  • Correlation between antibody staining and molecular status

  • Assessment of concordance rates

Following this comprehensive approach ensures reliable antibody performance in research applications and minimizes the risk of misleading results.